Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. An on-demand presentation will begin at 7:00 a.m. ET on January 10, with a replay available for two weeks afterward. Concert is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs using its DCE Platform, aimed at improving pharmacokinetic properties. Their lead candidate targets alopecia areata, an autoimmune skin condition. For details, visit www.concertpharma.com.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.

The webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the conference webcast will be available on Concert’s website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform^® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220102005016/en/

Justine Koenigsberg

(781) 674-5284

ir@concertpharma.com

Source: Concert Pharmaceuticals, Inc.

FAQ

What conference will Concert Pharmaceuticals participate in?

Concert Pharmaceuticals will participate in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022.

When will the on-demand presentation start for CNCE?

The on-demand presentation for Concert Pharmaceuticals (CNCE) will start at 7:00 a.m. ET on January 10, 2022.

How long will the webcast replay be available for CNCE?

The webcast replay of the presentation will be available on Concert Pharmaceuticals' website for two weeks following the event.

What is the focus of Concert Pharmaceuticals' lead product candidate?

Concert Pharmaceuticals' lead product candidate is focused on the treatment of alopecia areata, a serious autoimmune dermatological condition.

What unique platform does Concert Pharmaceuticals use for drug development?

Concert Pharmaceuticals uses the DCE Platform (deuterated chemical entity platform) for developing small molecule drugs.